Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide and Eltrombopag in Symptomatic Anemia in Low or Intermediate I MDS
NCT01772420Phase 2Completed
- Sponsor
- Albert Einstein College of Medicine
- Start
- Oct 2012
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenalidomide, eltrombopag in myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), anemia, sponsored by Albert Einstein College of Medicine. Started Oct 2012; status: completed.
02
Drugs
lenalidomideeltrombopag
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)anemia
Beyond the preview
Go deeper on NCT01772420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01772420.